DOCSLIB.ORG

Family Medicine (Fm-1) Multiple Choice Questions / Type I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Family Medicine (Fm-1) Multiple Choice Questions / Type I FAMILY MEDICINE (FM-1) MULTIPLE CHOICE QUESTIONS / TYPE I Select the correct answers to the following questions!!! ...each question may have more than one correct answer. FM-1.1. (g) Multiple Choice Question Renal calcification is a possible complication of: A) medullary cystic kidney disease B) renal tuberculosis C) sarcoidosis D) sickle cell anemia E) secondary hyperparathyroidism FM-1.2. Multiple Choice Question CV, IM Which of the following statements concerning chromosomes are correct? A) their number is normally 46 B) mosaicism is the coexistence of cells with different number of chromosomes within the same organism C) they are always identical in cells of the same phenotype D) nondisjunction must be followed by translocation E) they can be used as tumor markers FM-1.3. Multiple Choice Question IM Drugs with a bacteriostatic effect in regular doses include: A) tetracyclines B) cephalosporins C) sulfamethoxazole and trimethoprim (Sumetrolim) D) erythromycin E) amoxycillin FM-1.4. (a Multiple Choice Question Factors causing a susceptibility to urinary tract infect include: A) urinary tract obstruction B) diabetes mellitus C) hyperkalemia D) prolonged tetracycline therapy E) pregnancy 2 Multiple Choice Questions / Type I • FAMILY MEDICINE (FM-1) FM-1.5. Multiple Choice Question ~&, IM Case Study: The medical history of a 45-year-old male reveals episodes of vertigo and loss of consciousness associated with sweating. Possible causes of his symptoms include: A) hyperventilation B) hyperglycemia C) Zollinger-Ellison syndrome D) pheochromocytoma E) paroxysmal tachycardia FM-1.6. Multiple Choice Question IM Possible causes of hematemesis include: A) salicylate administration B) an oral iron supplement overdose C) severe burn injury D) Menetrier's disease (giant hypertrophic gastritis) E) feeding via a nasogastric tube FM-1.7. Multiple Choice Question PSY/IM The use of which of the following should be avoided in patients receiving monoamino-oxidase inhibitor therapy: A) cheese B) imipramine (Melipramin) C) phentolamine (Regitin) D) pethidine (Dolargan) E) sulphonamides FM-1.8. Multiple Choice Question IM Which of the following conditions are usually associated with purpura? A) Henoch-Schonlein syndrome B) hepatic cirrhosis C) systemic lupus erythematosus D) Addison's disease E) Raynaud's phenomenon FM-1.9. Multiple Choice Question IM Bone density is markedly increased in: A) osteopetrosis B) Paget's disease of the bone C) following the intake of a large amount of fluoride D) hyperparathyroidism E) renal osteodystrophy • (FM-1) FAMILY MEDICINE • Multiple Choice Questions / Type I FM-1.10!. O Multiple Choice Question IM Which of the following conditions is associated with a male-type distribution of hair in females? A) myxedema B) true hermaphroditism C) Laurence-Moon-Biedl syndrome D) Stein-Leventhal.syndrome (polycystic ovary) E) Cushing's syndrome FM-1.11. Multiple Choice Question IM` In which of the following conditions can central cyanosis be detected? A) methemoglobinemia B) ventilation-perfusion mismatch C) pulmonary arteriovenous fistula D) heatstroke E) heavy physical exercise FM-1.12. Multiple Choice Question PSY Which of- the following statements about delirium tremens are correct? A) chlormethiazole (Heminevrin) is suitable for treatment B) acoustic hallucinations are common C) visual hallucinations are common D) elbcroshock therapy is indicated in severe cases E) the condition may be fatal FM-1.13. Multiple Choice Question IM In which of the following conditions can renal failure be fatal? A) hypernephroma B) systemic lupus erythematosus (SLE) C) Weil's disease D) renal' tuberculosis E) accelerated hypertension FM-1.14. Multiple Choice Question IM Penicillin administration is the appropriate therapy in which of the following complications of syphilis? A) meningitis B) aneurysm of the aorta C) interstitial keratitis- D) condylomaaatum S) the generalized paralysis of psychotic patients 4 Multiple Choice Questions / Type I • FAMILY MEDICINE (FM-1) FM-1.15. Multiple Choice Question ~V, IM Characteristics of mycoplasma-pneumonia include: A) pleural effusion as a common complication B) the presence of cold agglutinins C) associated renal failure D) a good response to tetracyclines E) patients immunized against mycoplasma are resistant FM-1.16. Multiple Choice Question Which of the following statements about post-traumatic epilepsy are correct? A) it usually follows head trauma within a month B) the CT reveals the causative abnormalities C) it requires surgical therapy in most cases D) it responds poorly to standard anticonvulsive therapy E) the EEG reveals its characteristic changes FM-1.17. Multiple Choice Question (VI IM Macroglossia is a possible feature of which of the following conditions? A) acromegaly B) Marfan's syndrome C) Hurler's syndrome D) achondroplasia E) amyloidosis FM-1.18. Multiple Choice Question A paradoxically split second heart sound is a feature of., A) severe pulmonary stenosis B) a ventricular septal defect C) severe aortic stenosis D) a patent ductus arteriosus E) complete right bundle branch block FM-1.19. Multiple Choice Question ®' IM Bilateral parotid gland enlargement is a symptom of A) Mikulicz's syndrome B) infectious mononucleosis C) mumps D) brucellosis E) sarcoidosis • (FM-1) FAMILY MEDICINE • Multiple Choice Questions / Type 1 5 FM-1.20. Multiple Choice Question ~V' IM Which of the following statements about Conn's syndrome are correct? A) a high aldosterone level in the serum is a characteristic finding B) the plasma renin activity is elevated C) the associated hypertension is malignant in 10% of cases D) hyperkalemia is a common complication E) operative therapy is usually recommended FM-1.21. Multiple Choice Question IV, IM Recognized causes of nodular hepatomegaly include: A) postnecrotic cirrhosis B) primary biliary cirrhosis C) syphilis of the liver D) Weil's disease (Leptospira icterohemorrhagica) E) carcinomatous metastases of the liver FM-1.22. Multiple Choice Question CV, IM Which of the following symptoms are associated with Turner's syndrome? A) infantilism B) congenital abnormalities of the external genitalia C) an atrial septal defect D) retinitis pigmentosa E) a short stature FM-1.23. Multiple Choice Question IM , Symptoms characteristic of an acute exacerbation of ulcerative colitis include: A) the development of anemia B) the occurrence of vertigo following sulfasalazine therapy C) macroscopically detected blood in the feces D) the development of generalized eruptions E) an increased erythrocyte sedimentation rate FM-1.24. Multiple Choice Question PED The early manifestations of congenital syphilis include: A) oral eczema B) interstitial keratitis C) occipital lymphadenopathy D) Clutton-knee (Clutton's joint) E) chorioretinitis 6 Multiple Choice Questions / Type I • FAMILY MEDICINE (FM-1) FM-1.25. Multiple Choice Question ~V' IM/PED Which of the following statements about congenital hypertrophic pyloric stenosis are correct? A) it is more frequent in females B) there is an increased likelihood for any offspring to be similarly afflicted C) any vomit almost never contains bile D) the pyloric ring is rarely palpable E) the majority of patients require surgical therapy FM-1.26. Multiple Choice Question IM/PED Which of the following statements about renal disease are correct? A) a 3000 ml/24 h urine volume is a normal fmding B) the severity of proteinuria correlates with the severity of the responsible renal disease C) granular casts are observed exclusively in renal disease D) orthostatic proteinuria, if chronic, is abnormal E) Tamm-Horsfall protein is a normal constituent of the urine FM-1.27. Multiple Choice Question IM/PED Which of the following conditions is associated with true hematuria? A) urinary tract tuberculosis B) acute pyelonephritis C) acute cystitis D) malignant hypertension E) renal infarction FM-1.28. Multiple Choice Question IM/PED Which of the following statements about medullary cystic kidney disease are correct? A) the prognosis is usually poor B) it is usually manifested during childhood C) the diagnosis is based on the associated radiological findings D) renal calculi may be present E) renal function is frequently impaired FM-1.29. Multiple Choice Question CZF~ IM/PED In the carcinoid syndrome: A) mitral stenosis is a possible complication B) it may be diagnosed by measuring the vanillylmandelic acid (VMA) concentration in the urine • (FM-1) FAMILY MEDICINE • Multiple Choice Questions / Type 1 7 C) the application of methysergide (Deseril) is a possible thera- peutic intervention D) any associated alcohol intake can induce a facial blushing E) chronic dyspnea is a recognized complication FM-1.30. Multiple Choice Question Primary optic nerve atrophy is a recognized complication of: A) glaucoma B) disseminated sclerosis C) Paget's disease of the skull D) neurosyphilis E) ethambutol (Sural) therapy FM-1.31. Multiple Choice Question Recognized causes of motor neuropathy include: A) diabetes mellitus B) porphyria C) Guillain-Barre syndrome D) Friedrich's ataxia E) diphtheria FM-1.32. Multiple Choice Question ~&, IM/PED Possible causes of hypercholesterolemia include: A) primary biliary cirrhosis B) the nephrotic syndrome C) hyperthyroidism D) hepatocellular jaundice E) Gaucher's disease FM-1.33. Multiple Choice Question IM Which of the following statements about Chafrcot's joint are correct? A) it is caused by syringomyelia B) it is caused by diabetes mellitus C) it is more frequent in females than in males D) one of its complications is kyphosis
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
    [Show full text]
  • Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan
    Volume 3 | Number 3 Article 87 2012 Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan Albert I. Wertheimer Follow this and additional works at: http://pubs.lib.umn.edu/innovations Recommended Citation Ninan B, Wertheimer AI. Withdrawing Drugs in the U.S. Versus Other Countries. Inov Pharm. 2012;3(3): Article 87. http://pubs.lib.umn.edu/innovations/vol3/iss3/6 INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing. Commentary POLICY Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan, Pharm.D.1 and Albert I Wertheimer, PhD, MBA2 1Pharmacy Intern, Rite Aid Pharmacies, Philadelphia, PA and 2Temple University School of Pharmacy, Philadelphia PA Key Words: Drug withdrawals, dangerous drugs, UN Banned Drug list Abstract Since 1979, the United Nations has maintained a list of drugs banned from sale in member countries. Interestingly, there are a number of pharmaceuticals on the market in the USA that have been banned elsewhere and similarly, there are some drug products that have been banned in the United States, but remain on the market in other countries. This report provides a look into the policies for banning drug sales internationally and the role of the United Nations in maintaining the master list for companies and countries to use for local decision guidance. Background recently updated issue is the fourteenth issue, which contains At present, one of the leading causes of death in the U.S. is data on 66 new products with updated/new information on believed to be adverse drug reactions.1-14 More than 20 22 existing products.
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • POISONS LIST APPENDIX Amoebicides: Carbarsone
    POISONS LIST APPENDIX Amoebicides: Carbarsone Clioquinol and other halogenated hydroxyquinoline compounds Dehydroemetine; its salts Diloxanide; its compounds Dimetridazole Emetine Ipronidazole Metronidazole Pentamidine; its salts Ronidazole Anaesthetics: Alphadolone acetate Alphaxolone Desflurane Disoprofol Enflurane Ethyl ether Etomidate; its salts Halothane Isoflurane Ketamine; its salts Local anaesthetics, the following: their salts; their homologues and analogues; their molecular compounds Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts Benzocaine Bupivacaine Butyl aminobenzoate Cinchocaine Diperodon Etidocaine Levobupivacaine Lignocaine Mepivacaine Orthocaine Oxethazaine Phenacaine Phenodianisyl Prilocaine Ropivacaine Phencyclidine; its salts Propanidid Sevoflurane Tiletamine; its salts Tribromoethanol Analeptics and Central Stimulants: Amiphenazole; its salts Amphetamine (DD) Bemegride Cathine Cathinone (DD) Dimethoxybromoamphetamine (DOB) (DD) 2, 5-Dimethoxyamphetamine (DMA) (DD) 2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD) Ethamivan N-Ethylamphetamine; its salts N-Ethyl MDA (DD) N-Hydroxy MDA (DD) Etryptamine (DD) Fencamfamine Fenetylline Lefetamine or SPA or (-)-1-dimethylamino-1, 2-diphenylethane Leptazol Lobelia, alkaloids of Meclofenoxate; its salts Methamphetamine (DD) Methcathinone (DD) 5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD) Methylenedioxyamphetamine (MDA) (DD) 3, 4-Methylenedioxymetamphetamine (MDMA) (DD) Methylphenidate;
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Poisons. I No. 142 1967. No
    4'18 >, Poisons. i No. 142 1967. No. 142 [C] . '. , 'POISONS" ORDER, DATED 23RD MA.Y 1967, MADE BY THE MINISTE.R. OF HOME AFFAIRS UNDER SECTION 26A(6) OF THE, MEDlciNES, PHA~CY AND POISONS ACT (NORTHERN IRELAND) 1945. Whereas the Poisons Board, constituted' in accordanc~ with Section 26 of the Medicines, Pharmacy and Poisop.s ':Act (Northern' Ireland) 1945(a),' has recommended tome 'that the list· of -substances' which are to be treated as poisons fpr the purposes of the Pharmacy a~d Poisons Acts (Northern Ireland) 1925 to 1955(b) and known as "the Poisons ~hedule" for the 'purposes of those Acts should be amended so that <?ertain ,additionai substances should be inciuded in Part I of the said schedule (which Part consists of those Poisons which, subject to the provisions of the said Acts, ,are n6t to be sold except by a person who is an authoris,ed seller of .poisons) and in Part II thereof (which Part consists of those Poisons which, subject to the provisions of the said Acts, are not to be' sold except by authorised' sellers of poisons and those persons who are authorised 'by the local authority iihd whose names are entered in a register kept ·by.' tlielocal' authotityuilder Section 30 of the Act). Now, therefore, I, the Right HOnburable William Craig,'Ministet of Home A1fairs, in exercise of the powers conferred on me by Section '26A(6) of the Medicines, Pharmacy and Poisons Act (NortheIii It~land) ~945 ah~ of all other powers enabli~~r me hr that b~h~l! dp hyre~y Qrqe~' ~s fQl1~ws: Citation and Commencement , 1.
    [Show full text]
  • Drugs, Poisons and Controlled Substances Act 1981
    1834 ANNO TRICESIMO ELIZABETHAE SECUNDAE REGINAE VICTORIA Drugs, Poisons and Controlled Substances Act 1981 No. 9719 An Act to re-enact with Amendments the Law relating to Drugs, Poisons and Controlled Substances, to amend the Health Act 1958 and the Crimes Act 1958 and for other purposes. [Assented to 12 January 1982] BE IT ENACTED by the Queen's Most Excellent Majesty by and with the advice and consent of the Legislative Council and the Legislative Assembly of Victoria in this present ParUament assembled and by the authority of the same as follows (that is to say): Short tiUe. 1. (1) This Act may be cited as the Drugs, Poisons and Controlled Substances y4cM981. Commenco- (2) The several provisions of this Act shall come into operation ment. on a day or on the respective days to be fixed by proclamation or successive proclamations of the Governor in Council published in the Government Gazette. Arrangement (3) This Act is divided into Parts and Divisions as follows: of Act. Part I.—Introductory and Transitional ss. 2-11. Part II.—Poisons and Controlled Substances ss. 12-55. Division 1—Classification s. 12. Division 2—Authorized Persons ss. 13-14. Division 1981 Drugs, Poisons and Controlled Substances No. 9719 2335 Division 3—Poisons Advisory Committee ss. 15-18. Division 4—Licensed Persons s. 19. Division 5—Special Poisons s. 20. Division 6—Industrial, Educational and Laboratory Permits s. 21. Division 7—Issue of Licences and Permits s. 22. Division 8—Manufacture and Sale of Poisons or . Controlled Substances ss. 23-30. Division 9—Trade or Proprietary Poisons s.
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]